Correction to: Comparing Drug Shortages Experienced by Institutions With National Metrics
Oncologist. 2024 Mar 26:oyae058. doi: 10.1093/oncolo/oyae058. Online ahead of print.NO ABSTRACTPMID:38531814 | DOI:10.1093/oncolo/oyae058 (Source: The Oncologist)
Source: The Oncologist - March 27, 2024 Category: Cancer & Oncology Source Type: research

Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer
CONCLUSION: Combination therapy with first-generation EGFR-TKI and chemotherapy could be considered a neoadjuvant treatment option for patients with stage III-N2 EGFR-mutant NSCLC, exhibiting acceptable toxicity. However, regarding short-term efficacy, combination therapy did not demonstrate superiority over EGFR-TKI monotherapy. Long-term follow-up is warranted for a more accurate assessment of the DFS and OS.PMID:38529688 | DOI:10.1093/oncolo/oyae052 (Source: The Oncologist)
Source: The Oncologist - March 26, 2024 Category: Cancer & Oncology Authors: Yingqi Xu Hao Ji Yidan Zhang Liwen Xiong Baohui Han Hua Zhong Jianlin Xu Runbo Zhong Source Type: research

Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma
CONCLUSIONS: The concurrent high-dose external beam radiotherapy appears to safely enhance the effectiveness of atezolizumab plus bevacizumab for highly advanced patients with HCC. Further studies are warranted to confirm these findings.PMID:38530254 | DOI:10.1093/oncolo/oyae048 (Source: The Oncologist)
Source: The Oncologist - March 26, 2024 Category: Cancer & Oncology Authors: Chung-Wei Su Wei Teng Eric Yi-Liang Shen Bing-Shen Huang Po-Ting Lin Ming-Mo Hou Tsung-Han Wu Din-Li Tsan Chia-Hsun Hsieh Ching-Ting Wang Pei-Mei Chai Chun-Yen Lin Shi-Ming Lin Chen-Chun Lin Source Type: research

Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer
CONCLUSION: Combination therapy with first-generation EGFR-TKI and chemotherapy could be considered a neoadjuvant treatment option for patients with stage III-N2 EGFR-mutant NSCLC, exhibiting acceptable toxicity. However, regarding short-term efficacy, combination therapy did not demonstrate superiority over EGFR-TKI monotherapy. Long-term follow-up is warranted for a more accurate assessment of the DFS and OS.PMID:38529688 | DOI:10.1093/oncolo/oyae052 (Source: The Oncologist)
Source: The Oncologist - March 26, 2024 Category: Cancer & Oncology Authors: Yingqi Xu Hao Ji Yidan Zhang Liwen Xiong Baohui Han Hua Zhong Jianlin Xu Runbo Zhong Source Type: research

Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation
Oncologist. 2024 Mar 25:oyae014. doi: 10.1093/oncolo/oyae014. Online ahead of print.ABSTRACTMEK signaling pathway targeting has emerged as a valuable addition to the options available for the treatment of advanced cancers including melanoma and non-small cell lung cancer. Ophthalmologic monitoring of patients taking part in clinical trials of MEK inhibitors has shown that while ocular effects are common, generally emerging during the first days to weeks of treatment, the majority are either asymptomatic or have minimal visual impact and are benign, resolving without intervention or the need to reduce or stop MEK inhibitor ...
Source: The Oncologist - March 25, 2024 Category: Cancer & Oncology Authors: Karen W Jeng-Miller Miles A Miller Jeffrey S Heier Source Type: research

Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer
CONCLUSION: A majority of patients with mCRPC never receive BTAs prior to first SRE, despite universal access and availability of these agents in Ontario. These results highlight an opportunity to improve outcomes by emphasizing early introduction of BTA in patients with mCRPC being started on systemic therapy.PMID:38527096 | DOI:10.1093/oncolo/oyae036 (Source: The Oncologist)
Source: The Oncologist - March 25, 2024 Category: Cancer & Oncology Authors: William J Phillips Fred Saad Jennifer Leigh Alborz Jooya Colleen Webber Scott Morgan Robert MacRae Jean-Marc Bourque Peter Tanuseputro Michael Ong Source Type: research

Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology
CONCLUSION: CUP exhibits poor prognosis with limited benefits from standard treatment regimens. A significant proportion of CUPs carry actionable alterations, underscoring the importance of genomic profiling to gather additional treatment opportunities. In addition, immunotherapy might represent a valuable treatment option for a subset of CUP. Finally, accurate definition of sequencing methods and platforms is crucial to overcome NGS failures.PMID:38520742 | DOI:10.1093/oncolo/oyae038 (Source: The Oncologist)
Source: The Oncologist - March 23, 2024 Category: Cancer & Oncology Authors: Luca Boscolo Bielo Carmen Belli Edoardo Crimini Matteo Repetto Liliana Ascione Gloria Pellizzari Celeste Santoro Valeria Fuorivia Massimo Barberis Nicola Fusco Elena Guerini Rocco Giuseppe Curigliano Source Type: research

Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors
Oncologist. 2024 Mar 23:oyae046. doi: 10.1093/oncolo/oyae046. Online ahead of print.ABSTRACTThymic epithelial tumors (TETs) are rare tumors for which treatment options are limited. The ongoing need for improved systemic therapies reflects a limited understanding of tumor biology as well as the normal thymus. The essential role of the thymus in adaptive immunity is largely effected by its epithelial compartment, which directs thymocyte (T-cell) differentiation and immunologic self-tolerance. With aging, the thymus undergoes involution whereby epithelial tissue is replaced by adipose and other connective tissue, decreasing i...
Source: The Oncologist - March 23, 2024 Category: Cancer & Oncology Authors: Christopher S Nabel Jeanne B Ackman Yin P Hung Abner Louissaint Gregory J Riely Source Type: research

Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World
CONCLUSIONS: This updated analysis confirms the effectiveness of osimertinib in RW. Although the ICER of osimertinib seems not cost-effective, additional costs for the management of disease progression to old generation TKIs were not considered in this study. The BI-gap suggests RW mTTD as a more reliable measure for expense estimation.PMID:38520745 | DOI:10.1093/oncolo/oyae043 (Source: The Oncologist)
Source: The Oncologist - March 23, 2024 Category: Cancer & Oncology Authors: Giulia Pasello Martina Lorenzi Daniela Scattolin Alessandro Del Conte Fabiana Cecere Alberto Pavan Marianna Macerelli Valentina Polo Sara Pilotto Mariacarmela Santarpia Enrico Cumerlato Valentina Da Ros Giada Targato Alberto Bortolami Laura Bonanno Alessa Source Type: research

Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology
CONCLUSION: CUP exhibits poor prognosis with limited benefits from standard treatment regimens. A significant proportion of CUPs carry actionable alterations, underscoring the importance of genomic profiling to gather additional treatment opportunities. In addition, immunotherapy might represent a valuable treatment option for a subset of CUP. Finally, accurate definition of sequencing methods and platforms is crucial to overcome NGS failures.PMID:38520742 | DOI:10.1093/oncolo/oyae038 (Source: The Oncologist)
Source: The Oncologist - March 23, 2024 Category: Cancer & Oncology Authors: Luca Boscolo Bielo Carmen Belli Edoardo Crimini Matteo Repetto Liliana Ascione Gloria Pellizzari Celeste Santoro Valeria Fuorivia Massimo Barberis Nicola Fusco Elena Guerini Rocco Giuseppe Curigliano Source Type: research

Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors
Oncologist. 2024 Mar 23:oyae046. doi: 10.1093/oncolo/oyae046. Online ahead of print.ABSTRACTThymic epithelial tumors (TETs) are rare tumors for which treatment options are limited. The ongoing need for improved systemic therapies reflects a limited understanding of tumor biology as well as the normal thymus. The essential role of the thymus in adaptive immunity is largely effected by its epithelial compartment, which directs thymocyte (T-cell) differentiation and immunologic self-tolerance. With aging, the thymus undergoes involution whereby epithelial tissue is replaced by adipose and other connective tissue, decreasing i...
Source: The Oncologist - March 23, 2024 Category: Cancer & Oncology Authors: Christopher S Nabel Jeanne B Ackman Yin P Hung Abner Louissaint Gregory J Riely Source Type: research

Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World
CONCLUSIONS: This updated analysis confirms the effectiveness of osimertinib in RW. Although the ICER of osimertinib seems not cost-effective, additional costs for the management of disease progression to old generation TKIs were not considered in this study. The BI-gap suggests RW mTTD as a more reliable measure for expense estimation.PMID:38520745 | DOI:10.1093/oncolo/oyae043 (Source: The Oncologist)
Source: The Oncologist - March 23, 2024 Category: Cancer & Oncology Authors: Giulia Pasello Martina Lorenzi Daniela Scattolin Alessandro Del Conte Fabiana Cecere Alberto Pavan Marianna Macerelli Valentina Polo Sara Pilotto Mariacarmela Santarpia Enrico Cumerlato Valentina Da Ros Giada Targato Alberto Bortolami Laura Bonanno Alessa Source Type: research

Anticancer Drugs-Related Hypogonadism in Male Patients with Advanced Cancers on Active Treatment: A Systematic Review
CONCLUSION: Our research emphasizes the importance of evaluating the gonadal axis before treatment in patients considered at risk and testing it at regular intervals or in case of clinical suspicion.PMID:38518107 | DOI:10.1093/oncolo/oyae024 (Source: The Oncologist)
Source: The Oncologist - March 22, 2024 Category: Cancer & Oncology Authors: Giacomo Massa Luca Zambelli Ernesto Zecca Morena Shkodra Gabriele Tin è Augusto Caraceni Source Type: research

Anticancer Drugs-Related Hypogonadism in Male Patients with Advanced Cancers on Active Treatment: A Systematic Review
CONCLUSION: Our research emphasizes the importance of evaluating the gonadal axis before treatment in patients considered at risk and testing it at regular intervals or in case of clinical suspicion.PMID:38518107 | DOI:10.1093/oncolo/oyae024 (Source: The Oncologist)
Source: The Oncologist - March 22, 2024 Category: Cancer & Oncology Authors: Giacomo Massa Luca Zambelli Ernesto Zecca Morena Shkodra Gabriele Tin è Augusto Caraceni Source Type: research

The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype
Oncologist. 2024 Mar 18:oyae042. doi: 10.1093/oncolo/oyae042. Online ahead of print.NO ABSTRACTPMID:38498045 | DOI:10.1093/oncolo/oyae042 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Authors: Tito Fojo Meredith LaRose Susan E Bates Source Type: research